The Cost of Mental Health Care: A Cost-Sharing Law

By Staff Writer

March 31, 2024

Introduction:

The scarcity of mental health and substance use disorder (MH/SUD) treatment is a significant public health issue in the US, contributing to high levels of morbidity and mortality. Many people with MH/SUDs often hesitate to seek health care due to stigma and the lack of accessible clinicians. For those with commercial insurance, out-of-pocket expenses due to cost-sharing serve as another barrier. This article examines the mental health landscape in the US and the impact of cost-sharing laws on the cost of healthcare, focusing on the New Mexico No Behavioural Health Cost Sharing (NCS) law.

Who Receives Mental Health Care?

Persistent disparities exist in access to mental health care. In 2021, only 47% of US adults with mental illness received any mental health services. Workforce shortages contribute to this issue, with more than half of US residents living in areas short of mental health professionals. Even insured individuals often find it difficult to use their insurance for care, as nearly half of psychiatrists do not accept insurance. In 2021, 55% of people with serious mental illness who needed but did not receive mental health care cited unaffordability as the main barrier. Inadequate insurance payment and coverage was the primary obstacle for an additional 33%.

Towards More Equitable Access

The tradition of private practice psychiatry, coupled with the availability of cash-paying patients, exacerbates mental health workforce shortages, especially when demand outstrips supply. Despite expansions in insurance coverage and legal mandates that health plans include mental health care coverage, out-of-pocket costs remain a significant barrier. In 2021, racial and ethnic disparities in treatment rates were also evident.

The Implications of Cost-Sharing

Cost-sharing, which includes copayments, coinsurance, and deductibles, is designed to curb the overuse of health care. However, for individuals with MH/SUDs, cost-sharing can discourage the use of effective treatments. The RAND Health Insurance experiment in the 1970s demonstrated this, showing that higher cost-sharing led to larger reductions in mental health care than other health care use.

The New Mexico No Behavioural Health Cost Sharing Law

In April 2021, New Mexico passed the NCS law, prohibiting cost-sharing for MH/SUD treatment for individuals with commercial insurance plans. This law was a response to the need to reduce the costs of MH/SUD treatment, given the vast personal and societal costs of these conditions. However, the impact of the law on patient outcomes is yet to be fully understood.

The Impact of the New Mexico No Behavioural Health Cost Sharing Law

In order to lower MH/SUD treatment costs, the NCS was passed. The NCS applies solely to state-regulated commercial insurance plans, including fully insured, employer-sponsored plans, individual market plans, and New Mexico state employee health plans (SEHPs), which cover public school employees. The data suggests that the NCS effectively shielded patients from out-of-pocket spending on medications for MH/SUDs. A recent study discovered that the average out-of-pocket expense for psychotropic medications decreased by $6.37, or 85.6%, when compared to New Mexico federal employees who were not impacted by NCS. However, the overall volume of dispensed MH/SUD prescription drugs did not significantly change.

Conclusion:

New Mexico’s NCS law provides a case study on how legislation can tackle financial obstacles to mental health care. It has effectively cut down out-of-pocket costs for psychotropic drugs. However, the total amount of dispensed MH/SUD prescription drugs hasn’t changed significantly. This situation highlights the complex nature of mental health care access. It’s not just about cost, but also about professional availability and lingering mental health stigma. We have yet to see the law’s effect on non-drug services. Yet, the initial success in lessening the financial strain of medication signals a hopeful beginning. Despite this, the data on mental health care access indicates a long road to equitable mental health care. It’s clear that while laws like NCS can contribute, we need a multi-faceted strategy. This strategy should address workforce shortages, insurance coverage, and societal stigma.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.